Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bacillus cereus is a ubiquitous gram-positive, spore-forming bacterium found in soil. While it is a known foodborne pathogen capable of causing severe systemic infections, particularly in immunocompromised individuals and preterm neonates, it is also investigated for its therapeutic potential as a probiotic. In this capacity, it is studied for its ability to modulate gut microbiota to treat conditions such as constipation in patients with type 2 diabetes mellitus and diarrhea-predominant irritable bowel syndrome (IBS-D). It has also been evaluated for preventing treatment-associated diarrhea, such as that caused by afatinib. Beyond its medical applications, Bacillus cereus is also involved in industrial processes like poly-3-hydroxybutyrate (PHB) production and nonylphenol biodegradation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bacillus cereus.